



Protection Without the Injection

Help Protect Your Patients Against the Flu With FLUMIST

Individual results may vary.

For the prevention of
influenza in persons
2 to 49 years of age.

.....
Available for either
in-office or
in-home use.^{1,2}

A caregiver should administer FluMist to
individuals 2 through 17 years of age.

The only
FDA-approved nasal
spray flu vaccine.¹

.....
ACIP and AAP
recommended.

20+ years of real-world
use since its US approval
in 2003.¹

.....
200+ million doses
distributed across
34 countries.^{3,4}

Vaccine formulation options do not imply comparable efficacy, safety, or FDA-approved indications.

AAP = American Academy of Pediatrics; ACIP = Advisory Committee on Immunization Practices; FDA = US Food and Drug Administration.

INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

IMPORTANT SAFETY INFORMATION


- Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
- When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#).



Offering Intranasal Flu Vaccination May Help Increase Vaccination Uptake Among Your Patients⁵

Based on a survey, when both a nasal spray and an injectable option were made available for flu vaccination, unvaccinated individuals were more likely to get vaccinated.^{6,*}



That's an increase nationally of...


~2.3 million
children


~4.9 million
adults


~1.4 million
Black, Hispanic, and AAPI adults


~2.3 million
Black, Hispanic, and AAPI adults

Vaccine uptake information was approximated by Ipsos' KnowledgePanel®, which was supported by AstraZeneca.


*Anticipated likelihood projected based on Clancy-scale-calibrated response among those not already vaccinated (mean).

IMPORTANT SAFETY INFORMATION (continued)

- In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
- Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#).

Comparable Vaccine Effectiveness of LAIV and IIV Proven Consistent Across Multiple Seasons⁷⁻¹²



Results are descriptive only and based on separate studies conducted under different conditions and populations rather than direct head-to-head clinical trials. This information may not be all-inclusive as it is intended to be a concise summary of representative data on vaccine effectiveness. VE CIs truncated at 0 to enable graphical display.

All Influenza (2-17 years)

■ LAIV

■ IIV

*California data are interim, whereas UK data reflect end of season. [†]8% of doses were FluMist.

CI = confidence interval; Dept. = department; IIV = inactivated influenza vaccine; LAIV = live attenuated influenza vaccine; UK = United Kingdom; VE = vaccine effectiveness.

IMPORTANT SAFETY INFORMATION (continued)

- The effectiveness of FLUMIST has not been studied in immunocompromised persons
- The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
- FLUMIST may not protect all individuals receiving the vaccine

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#).




FluMist.
Influenza Vaccine
Live, Intranasal

Expanding Access for the Right Patients With FluMist Home

FLUMIST provides flexibility to meet families where they are—in your office or at home.

FluMist Home offers the same FDA-approved vaccine, delivered for Self- or Caregiver Administration through a seamless, easy-to-navigate process.¹³

[Click here](#) or scan
the QR code to
Learn More about
FluMist Home.



IMPORTANT SAFETY INFORMATION (continued)

- The most common solicited adverse reactions ($\geq 10\%$ in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever $>100^\circ\text{F}$ (children ages 2-6 years), and sore throat (adult ages 18-49 years)

Please see Important Safety Information throughout and full [Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#).

You may [report side effects related to AstraZeneca products](#).

References: 1. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist[®]; Fluenz[™]): a review of its use in the prevention of seasonal influenza in children and adults. *Drugs*. 2011;71(12):1591-1622. doi:10.2165/11206860-000000000-00000. 2. FDA press release. FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration. Accessed May 12, 2026. <https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-spray-influenza-vaccine-self-or-caregiver-administration>. 3. AstraZeneca Press release. US Food and Drug Administration accepts for review AstraZeneca's Supplemental Biologics License Application for self-administration of FluMist Quadrivalent. Accessed July 14, 2026. 4. AstraZeneca. FluMist approved for self-administration in the US. Accessed April 10, 2026. <https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html>. 5. FLUMIST Prescribing Information. 6. Newall M et al. Ipsos. Expanding flu vaccine. Accessed May 12, 2026. <https://www.ipsos.com/en-us/news-polls/expanding-flu-vaccine>. 7. Department of Defense (DOD). Defense Health Agency. March 12, 2026 (not available online). 8. Zhu S, Quint J. Interim influenza vaccine effectiveness against laboratory-confirmed influenza, California, October 2024–January 2025. Advisory Committee on Immunization Practices Meeting. Accessed May 9, 2026. <https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/03-zhu-influenza-508.pdf>. 9. UK Health Security Agency. Official Statistics. Surveillance of influenza and other seasonal respiratory viruses in the UK, winter 2023 to 2024. Accessed May 9, 2026. <https://www.gov.uk/government/statistics/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2023-to-2024>. 10. UK Health Security Agency. Official Statistics. Surveillance of influenza and other seasonal respiratory viruses in the UK, winter 2024 to 2025. Accessed May 9, 2026. <https://www.gov.uk/government/statistics/influenza-in-the-uk-annual-epidemiological-report-winter-2024-to-2025/influenza-in-the-uk-annual-epidemiological-report-winter-2024-to-2025>. 11. Zhu S et al. *MMWR Morb Mortal Wkly Rep*. 2026;75(9):124–128. 12. Lucaccioni H et al. *Euro Surveill*. 2026;31(7):2600109. 13. Data on File, REF-263898, AstraZeneca Pharmaceuticals LP.

Who is the right patient for FluMist Home?

PATIENT PROFILE

Family With Multiple Children



FluMist Home can help remove the coordination barrier so all eligible children in a household can get vaccinated.

A caregiver should administer FluMist to individuals 2 through 17 years of age.

PATIENT PROFILE

Out-of-Season Wellness Visit



FluMist Home bridges the timing gap; prescribe at today's visit and deliver closer to flu season.

PATIENT PROFILE

Busy Young Professional



FluMist Home eliminates the second-appointment barrier, delivered at home on their schedule.

Hypothetical patient profiles for illustrative purposes only. All clinical decisions should be guided by the FDA-approved label, public health recommendations, and an individual patient assessment.